Amino Acid Metabolism Disorders is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Amino Acid Metabolism Disorders have a 90% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Amino Acid Metabolism Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Amino Acid Metabolism Disorders overview

Amino acids are building blocks of proteins and enzymes. Metabolism of amino acids results in energy production and other mechanisms. Any disturbance in this pattern results in metabolic disorders. These are a group of inherited diseases. Amino acid metabolic disorders include Phenylketonuria, maple syrup urine disease, citrullinemia (CIT), ornithine Transcarbamylase deficiency, and argininosuccinate lyase (ASL) deficiency. All these conditions are genetically inherited autosomal /X-linked recessive. Diagnosis is done by lab examination of urine, blood analysis, and biochemistry reports. Low protein diet is recommended and in severe cases liver transplant is the option.

For a complete picture of PTSR and LoA scores for drugs in Amino Acid Metabolism Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.